A randomized, double-blind comparison of nadifloxacin 1% cream alone and with benzoyl peroxide 5% lotion in the treatment of mild to moderate facial acne vulgaris by Yazıcı Özgen, Züleyha & Gürbüz, Oya
ORIGINAL ARTICLE / ÖZGÜN ARAŞTIRMA
17
Marmara Medical Journal (2013) 26:17-20
DOI: 10.5472/MMJ/2012.02649
Introduction
Topical agents are the first-line therapy in the management of 
mild to moderate acne. Retinoic acids, benzoyl peroxide, and 
topical antibiotics are the most frequently used topical agents. 
As Propionibacterium acnes resistance to common antibiotics 
has significantly increased over the past 30 years, due to their 
widespread use in acne treatment, new treatment strategies 
have been developed to combine topical antibiotics with 
anti-inflammatory and comedolytic agents, to minimize the 
development of P.acnes resistance [1-5]. Benzoyl peroxide; 
with its antibacterial, sebostatic and comedolytic effects, 
supresses P.acnes by oxidative mechanism. There is still no 
evidence that microorganisms become resistant to benzoyl 
peroxide, despite its widespread use in the last 5 decades.
Nadifloxacin, a new fluoroquinolone antibiotic, has been 
developed for topical administration. It is effective against 
Gram-positive, Gram-negative and anaerobic bacteria, 
including P acnes [6]. Since 1995, it has been licensed as 
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ABSTRACT
Objective: To compare the efficacy of nadifloxacin alone and with 
benzoyl peroxide in the treatment of mild to moderate facial acne 
vulgaris. 
Patients and Methods: This double-blind, randomized study 
was conducted in a total of 93 acne patients, with at least 10 
inflammatory lesions, but no more than 3 nodules or cysts on the 
face. All patients were instructed to apply nadifloxacin 1% cream 
twice daily and randomized to apply either benzoyl peroxide 5% 
lotion or its vehicle once daily for 8 weeks. 
Results: The mean percent reduction in inflammatory lesions 
were 22.08% in the nadifloxacin group (n=46) and 53.5% in the 
nadifloxacin+benzoyl peroxide group (n=47). Five (10.9%) 
patients in the nadifloxacin group and 18 (38.3%) patients in the 
nadifloxacin+benzoyl peroxide group achieved a 50% and greater 
reduction in the inflammatory lesion count. 
Conclusion: Both treatment regimens were statistically 
effective, but a significantly greater reduction of the inflammatory 
lesions was seen in the nadifloxacin+benzoyl peroxide group. The 
number of patients who achieved a 50% and greater reduction 
in inflammatory lesion count was significantly higher in the 
nadifloxacin+benzoyl peroxide group. Both treatment regimens 
were well tolerated with mild side effects.
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ÖZET
Amaç: Hafif-orta şiddetli akne vulgaris tedavisinde nadifloksasin 
kremin tek başına veya benzoil peroksit ile birlikte kullanımının 
etkinliğini karşılaştırma. 
Hastalar ve Yöntem: Çift kör, randomize çalışma, toplam 
93 hasta 2 grup olarak ya nadifloksasin kremi ya benzoil peroksit 
losyonun baz formu ya da benzoil peroksit ile birlikte 8 hafta süre 
ile kullandı.
Bulgular: İnflamatuar lezyonlar tek başına nadifloksasin 
kullanan grupta(n=46) %22, 08, nadifloksasin+benzoil peroksit 
kullanan grupta(n=47) %53,5 oranında azaldı. Tek başına 
nadifloksasin kullanan grupta beş (%10,9), nadifloksasin+benzoil 
peroksit kullanan grupta 18(%38,3)hastada inflamatuar lezyonlarda 
%50 ve üzeri azalma görüldü. 
Sonuç: Her iki tedavi de istatistiksel olarak etkili bulundu ancak 
nadifloksasin+benzoil peroksit grubunda belirgin olarak inflamatuar 
lezyonlarda azalma görüldü. Her iki tedavi de hafif yan etkiler ile 
çok iyi tolere edildi.
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Acne and nadifloxacin
acne medication in many countries, including Japan, Spain, 
Germany, Mexico, Bulgaria, Korea and Turkey. Clinical 
studies comparing the efficacy of nadifloxacin with either 
placebo or other topical agents have been very limited. So far, 
there has been no clinical study evaluating the combined use 
of nadifloxacin with an anti- inflammatory and comedolytic 
agent such as benzoyl peroxide.
The primary purpose of this study was to compare the 
efficacies of nadifloxacin alone and with benzoyl peroxide in 
the treatment of mild to moderate facial acne vulgaris. 
Patients and Methods
Study design
Randomized, double-blind, parallel group study, in which 
the patients were randomly assigned to use either nadifloxacin 
1% cream alone or with benzoyl peroxide 5% lotion during 
an 8-week treatment period. The study was conducted 
at Marmara University Hospital Dermatology outpatient 
clinic and approved by the appropriate institutional ethics 
committee. All patients and also the parents of patients under 
18 years old provided written informed consent in order to 
participate.
The number of patients in the study group was calculated 
as 45 in each group in order to detect a 30% difference in 
inflammatory lesions count at 5% significance level with 
80% power.
Inclusion and exclusion criteria
Patients aged 14-40 years with mild to moderate acne 
vulgaris of the face; with at least 10 inflammatory lesions 
but no more than three nodulocystic lesions were eligible to 
enroll for the study. A washout period of at least 2 weeks for 
topical acne therapies, 4 weeks for oral antibiotics and laser 
or chemical peelings, 3 months for estrogens or birth control 
pills and 6 months for oral retinoids was allowed. Patients 
were excluded if they had pure comedonal acne, truncal acne 
requiring systemic treatments and other facial skin disorders. 
Women were excluded if they were pregnant or nursing and 
showed clinical signs of hyperandrogenism.
Treatment protocol
Patients were randomized consecutively in a 1: 1 ratio 
to apply either nadifloxacin 1% cream (Nadixa 1% cream; 
Adeka) twice daily and benzoyl peroxide 5% lotion (Aknefug 
BP5 lotion; Orva) once daily (5 minutes after nadifloxacin) 
or nadifloxacin 1% cream twice daily and vehicle of benzoyl 
peroxide once daily for 8 weeks according to a computer 
generated list. The integrity of the blinding was ensured 
by packaging the benzoyl peroxide lotion and its vehicle in 
identical bottles and allocating a different person to dispense 
the medications. Patients were instructed to wash their faces 
with tap water and dry and then apply the medications to the 
whole face. The same moisturizer (Neutrogena oil free ™) 
was allowed to be used by all, if needed. 
Assessment of efficacy and tolerability
Patients were evaluated at weeks 0, 2 and 8 of the 
treatment period. To assess the efficacy, inflammatory 
and noninflammatory lesions were counted on the face 
excluding the nasal region. At the end of the treatment 
period, the percentage of reductions in inflammatory and 
noninflammatory lesions was calculated. In addition, global 
improvement was rated by the patients using a six-points 
scale (worsening, no improvement, slight improvement, 
moderate improvement, good improvement, clearance) at 
the end of the treatment. For the safety measurements, local 
side effects were classified as erythema, desquamation, 
pruritus and burning sensation, with each being assessed for 
the severity using a five point scale (none, very slight, mild, 
moderate, severe) and for the duration. Patients were also 
asked for other adverse events.
The primary efficacy variable was the percentage of the 
reduction in inflammatory lesions and the secondary efficacy 
variable, was the number of patients who achieved 50% and 
a greater reduction in inflammatory lesions after the 8 week-
treatment period. 
Statistical analysis
Analyses for efficacy and safety were performed on week 
8. Data for the intent-to-treat (ITT) population included 
all randomized patients who were supplied with study 
medications. The “last observation carried forward (LOCF)“ 
methodology was used for the ITT population analysis (lesion 
counts), to account for missing data or for data from patients 
who withdrew from the study. The t-test and X² test was 
performed to compare the groups. The ANCOVA test was 
performed to analyze the variables that were incomparable. 
P<0.05 was considered significant. 
Results
Demographic features
A total of 93 patients; 46 (30 females, 16 males) in the 
nadifloxacin group, and 47 (27 females, 20 males) in the 
nadifloxacin+benzoyl peroxide group were involved in 
the study. Fourteen patients were dropped due to follow-
up failure (3 patients), incompliance (10 patients), and 
side effects (1 patient). A total of 79 patients completed 
the 8 week-treatment. The baseline characteristics of 
the patients are summarized in Table І. The treatment 
groups were comparable in respect to the demographic 
characteristics and baseline number of inflammatory lesions, 
but not in respect to the noninflammatory lesions. The mean 
number of noninflammatory lesions were higher in the 
nadifloxacin+benzoyl peroxide group.
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Efficacy evaluation
The number of inflammatory and noninflamatory lesions 
was significantly reduced at the end of the treatment period 
in both treatment groups. The mean percent reduction in 
inflammatory and noninflammatory lesions was 22.08% 
and 7.6% in the nadifloxacin group, and 53.5% and 34.8% 
in the nadifloxacin+benzoyl peroxide group respectively 
(Figure 1,2). The reduction rates for inflammatory and 
noninflammatory lesions were significantly superior for 
nadifloxacin+benzoyl peroxide comparing to nadifloxacin 
alone (all, P<.001). Five patients (10.9%) in the nadifloxacin 
group and 18 patients (38.3%) in the nadifloxacin+benzoyl 
peroxide group achieved 50% and greater reduction in 
inflammatory lesions count. There was a statistically 
significant difference in favor of the nadifloxacin+benzoyl 
peroxide group (P=.002). Global improvement was rated 
by 89 patients, a significantly greater number of patients 
using nadifloxacin+benzoyl peroxide reported “good” 
or “moderate” improvement compared to patients using 
nadifloxacin alone (68% vs 24%; P<.001). None of the 
patients in the nadifloxacin+benzoyl peroxide group but four 
patients in the nadifloxacin group reported “worsening”. 
None of the patients in the study groups defined “clearance”.
Safety evaluation
The number of patients experiencing at least one adverse 
event was significantly higher in the nadifloxacin+benzoyl 
peroxide group with 61.7% vs 37% (P=.002). One patient in 
the nadifloxacin+benzoyl peroxide group withdrew because 
of “severe” burning sensation. Four patients had to use 
moisturizer for “moderate” desquamation and erythema in the 
nadifloxacin+benzoyl peroxide group. The other side effects 
were “very slight” or “mild”. In general, all were observed at 
the initial treatment phase and resolved with time.
Discussion 
In this study, we observed the superior efficacy of nadifloxacin 
1% cream+benzoyl peroxide 5% lotion compared to 
nadifloxacin 1% cream+vehicle of benzoyl peroxide in the 
treatment of mild to moderate facial acne vulgaris. The mean 
percentage of reduction in inflammatory lesion was 22.08% 
and 53.5% in the nadifloxacin and combination group 
respectively. Combinations of topical antibiotics and benzoyl 
peroxide or retinoids are the current standard regimens for 
the treatment of mild to moderate acne vulgaris [1,2]. Since 
they targeted multiple pathogenetic factors, greater and faster 
efficacy were provided by these combinations. Development 
of antibiotic-resistant P. acnes can also be prevented by these 
combined topical treatments. At present, to our knowledge, 
there has been no published study evaluating the combination 
of nadifloxacin, a new topical antibiotic, with benzoyl 
peroxide and comparing it to nadifloxacin alone.
Nadifloxacin, a new broad spectrum antibiotic was 
licensed as acne medication in Turkey in 2008. A double-
blind, vehicle-controlled study showed nadifloxacin cream 
to be superior as clinically and bacteriologically to vehicle 
[7]. A recent split face, double-blind vehicle controlled with 
clinical and histological evaluation in 37 Korean patients , 
supported the previous data[8]. Plewig et al. noted similar 
efficacy in reducing inflammatory lesion count with both 
nadifloxacin 1% cream (66.7%) and erythromycin 2% cream 
(64.7%) and superior efficacy of nadifloxacin in reducing P. 
acnes in 474 participiants [9]. A recently published Turkish 
data verified the similar clinical efficacies of nadifloxacin 1% 
cream and erythromycin 4% gel [10]. In a study by Bojar et 
al, erythromycin-resistant P. acnes were isolated from 27.9% 
of erythromycin treated subjects, whereas no nadifloxacin-
Table І. The baseline characteristics of the patients.
  Nadifloxacin
            (n=46)
Nadifloxacin+
Benzoyl peroxide          
         (n=47)
Age (mean) (min-max)    19.67 (14-29)     19.06 (14-29)
Sex
              F (n) (%)
              M (n) (%)
   30 (65.2%)
   16 (34.8%)
    27 (57.4%)
    20 (42.6%)
Duration of acne  
(mean-month)
   52.96     55.23
Inflammatory lesion 
count (mean) (min-max)
Noninflammatory  lesion 
count (mean) (min-max)
Total lesion count (mean)
(min-max)
   21.52 (10-50)
   33.67 (5-150)
   55.13 (17-179)
 23.98(10-53) p=0.192
 49.11(4-162) p=0.032
 73.38(19-190) p=0.022
Figure 1. Reduction of inflammatory lesion count in the treatment groups.
Figure 2. Reduction of noninflammatory lesion count in the treatment 
groups.
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resistant P. acnes were isolated from nadifloxacin treated 
subjects after a 12 week-treatment [11]. An in-vitro study 
from Germany showed that P. acne has not developed 
resistance to nadifloxacin during the last two years of use in 
their country [12].
 In this study, it has been shown that inflammatory and 
noninflammatory lesions were reduced in a ratio of 22.08% 
and 7.6% in the nadifloxacin group, 53.5% and 34.8% in 
the nadifloxacin+benzoyl peroxide group respectively. The 
efficacy of nadifloxacin cream in our study was lower than in 
the previous studies. The efficacy of topical antibiotics such 
as erythromycin and clindamycin has been documented in 
a range of 35-70%. The efficacy of benzoyl peroxide alone 
36-60% when combined with erythromycin or clindamycin 
was 54-75% in well designed studies in the literature [13-19]. 
The efficacy of vehicle has also been found to be 5-35% in 
these studies. In the light of these data, nadifloxacin in our 
study can be assumed to have similar efficacy with vehicles. 
The question was if nadifloxacin had any additive effect to 
the results of our nadifloxacin+benzoyl peroxide group. A 
four -armed study with an additional two treatment groups 
(benzoyl peroxide and vehicle alone) would be more suitable 
to answer this question. Unfortunately, we could not add 
these groups to the study because of technical problems. 
The treatment duration was lower in our study compared 
to a previous study (8 vs 12 weeks respectively) [9]. Topical 
antibiotics are generally recommended for 8 weeks with the 
limitation of maximum 12 weeks by the authors [1,2,20]. 
We observed maximum improvement with all treatment 
regimens at week 2. There was no additional statistically 
significant improvement after 2 weeks of nadifloxacin use. 
We also provided the subject number as has been mentioned 
in the study design. We believe that treatment duration and 
the number of subjects were sufficient to show the difference 
in efficacies in our study. 
Although nadifloxacin is still superior to other antibiotics 
in the rate of resistant pathogens, this fact might be due to its 
very recent availability among the other acne medications in 
the market  [21]. Judging from the perspective of effectiviness, 
resistance and cost; the currently recommended therapy for 
mild to moderate acne is to use topical retinoids, benzoyl 
peroxide and/or antibiotics together [1,2,20].
 In conclusion; although nadifloxacin has lower 
efficacy when used alone, it might have an additive effect 
in combination treatment of mild to moderate acne. Well 
designed, comparative studies and cost-effectivity analysis 
are still needed to include nadifloxacin as a specific agent. 
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